Todd Usen joined Minerva Surgical as President & CEO on January 3, 2023. Prior to Minerva Todd served as CEO at Activ Surgical, where he oversaw the FDA clearance of its ActivSight technology, as well as leading four Series fundraising rounds totaling over $92M.
Todd came to Activ Surgical after serving as the President of the Medical Systems Group at Olympus Corporation of the Americas, where he helped lead the expansion from 6 medical divisions to 11 in 3.5 years. Prior to joining the Olympus Corporation, Todd held the position of President, Orthopedics, at Smith and Nephew, overseeing the Total Joint, Sports Medicine and Trauma divisions.
Todd has held several other vital positions for Smith and Nelson including Senior Vice President and General Manager, Joint Reconstruction; Senior Vice President, Sports Medicine; and Senior Vice President, Endoscopy.
Prior to Smith and Nephew, Todd worked for Boston Scientific as the Vice President of Sales for the Neurovascular Division, Director of Endoscopy Sales, and Global Manager of Field Development.
Todd completed his MBA at Pepperdine University and graduated Magna Cum Laude from the Isenberg School at the University of Massachusetts, While at UMASS he played baseball and was recognized and inducted into the “Outstanding College Students of America” and the Golden Key National Honor Society.
Catherine Coste has served as a member of our board of directors since February 2021. Ms. Coste retired from Deloitte and Touche LLP in 2020, where she was a senior partner and served as one of Deloitte’s Life Sciences Industry Executive Leaders. She spent 32 years in both corporate and professional services positions leading global finance, internal audit and operations teams. During her career at Deloitte, Ms. Coste was directly involved with over 30 life science corporations, the majority of which were large-cap and medium-cap public corporations. Ms. Coste also has extensive public company board experience, often attending multiple board committee meetings per month, and currently serves as a director and audit committee chair for Biomerica, Inc. Ms. Coste also has extensive experience in Sarbanes-Oxley compliance, corporate risk analysis and management, cyber risk assessment, fraud prevention, IT systems analysis and upgrades, internal controls, and corporate governance. Ms. Coste is a Certified Public Accountant. Ms. Coste earned her B.A. in Business Administration, Accounting, from California State University, Hayward.
Uri Geiger brings extensive entrepreneurial, management and investment know-how, having created and built many successful medical device enterprises.
Prior to founding Accelmed, Dr. Geiger founded served as CEO of Exalenz Bioscience Ltd. (TASE:EXEN), developer of an innovative breath-based technology for diagnosing liver and gastrointestinal disorders which Dr. Geiger took public in 2007 and later sold to Meridian (NASDAQ: VIVO). Prior to Exalenz, Dr. Geiger co-founded and was the CEO of GalayOr Networks, a developer of optical components, sold in 2003 to MEMSCAP (EuroNext: MEMS). Dr. Geiger is also the founding partner of Dragon Variation Fund, one of Israel’s first hedge funds, which was sold to Migdal in 2007. Dr. Geiger worked on Wall Street during the 1990s, where he gained a broad understanding of capital markets and significant experience, which he put to use after returning to Israel in 1999.
Dr. Geiger was formerly an adjunct professor at the Recanati Business School at Tel Aviv University, where he lectured on private equity and venture capital. He is the author of the books: Startup Companies and Venture Capital (Tel Aviv University Press, 2001) and From Concept to Wall Street (Financial Times – Prentice Hall, 2003). He earned his doctorate from New York’s Columbia University Center for Law & Economics, where he majored in global equity markets. Dr. Geiger served as a major in the Israeli Air Force.
Dr. Geiger is also involved in an extensive philanthropic activity and is the Founder & Chairman of Friends of Poriya Medical Center in the US.
Dan has over 25 years of experience in medical technology finance, investment banking, and private equity. Dan was the Israeli GM of China-based Fosun Pharma, and a principal at France-based Credit Agricole. Dan holds an MBA from ESSEC MBA, a BSc in Computer Sciences, a BA in Mathematics, and graduate studies in Biology.